Key facts
- This page summarizes Eric J. Loumeau's Form 4 filing for ANAPTYSBIO, INC (ANAB).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 13 Feb 2026, 16:05.
Key filing fact
Ownership activity is grounded in SEC Form 4 disclosures.
Shares, units, or other non-derivative securities reported in this filing.
Options Exercise
Sale
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
Options Exercise
Additional SEC filing notes
Rule 10b5-1 trading plan
These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.
Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).
Footnote F1
The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the reporting person dated April 11, 2025.
Footnote F2
The stock option is fully vested.
Footnote F3
In addition to the options to purchase a total of 35,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 436,010 shares of common stock, which options vest according to their terms.